SCI时时刷

search
+
Correction to: Motixafortide: First Approval
Correction to: Motixafortide: First Approval
In the published PDF version, Section 2.1 Pharmacodynamics, second paragraph, sixth s...
Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension
Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension
A randomized, double-masked, multicenter, phase 2 trial to evaluate the long-term safety and efficacy of travoprost intrao...
Nedosiran: First Approval
Nedosiran: First Approval
Nedosiran (RIVFLOZA™), a once-monthly subcutaneous small interfering RNA (siRNA) therapy, is being developed by Dice...
Waldenström Macroglobulinemia: Targeted Agents Taking Center Stage
Waldenström Macroglobulinemia: Targeted Agents Taking Center Stage
With the worldwide approval of the oral covalent Bruton tyrosine kinase (BTK) inhibitors ibrutinib and zanubrutinib for tr...
Iruplinalkib: First Approval
Iruplinalkib: First Approval
Iruplinalkib (Trade name: 启欣可®; Code name: WX-0593), a highly selective oral anaplastic lymphoma...
Momelotinib: First Approval
Momelotinib: First Approval
Momelotinib (OJJAARA) is an oral Janus kinase 1 and 2 (JAK1/JAK2) and activin A receptor, type I (ACVR1) inhibitor that ha...
Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults
Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults
Mitapivat (Pyrukynd®), an oral, allosteric activator of pyruvate kinase (PK), is approved in the USA for the treatmen...
Motixafortide: First Approval
Motixafortide: First Approval
Motixafortide (APHEXDATM) is a selective C-X-C motif chemokine receptor 4 (CXCR4) inhibitor being developed by BioLineRx u...
Correction: Elacestrant: First Approval
Correction: Elacestrant: First Approval
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International ...
Sunvozertinib: First Approval
Sunvozertinib: First Approval
Sunvozertinib (舒沃哲®) is an oral, irreversible, epidermal growth factor receptor (EGFR) tyrosine ...
Aetiology of Significant Liver Test Abnormalities in a Single-Centre Cohort of People with Cystic Fibrosis Exposed to Elexacaftor/Tezacaftor/Ivacaftor, Utilizing the Updated RUCAM
Aetiology of Significant Liver Test Abnormalities in a Single-Centre Cohort of People with Cystic Fibrosis Exposed to Elexacaftor/Tezacaftor/Ivacaftor, Utilizing the Updated RUCAM
The cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulator elexacaftor/tezacaftor/ivacaftor (E/T/I) has...
Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval
Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 Internationa...
Current and Emerging Treatment Options for Uterine Fibroids
Current and Emerging Treatment Options for Uterine Fibroids
Uterine fibroids are the most common benign neoplasm of the female reproductive tract in reproductive age women. Their pre...
Elranatamab: First Approval
Elranatamab: First Approval
Elranatamab (elranatamab-bcmm; ELREXFIO™) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T cell engag...
Correction to: Rozanolixizumab: First Approval
Correction to: Rozanolixizumab: First Approval
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International ...
Zuranolone: First Approval
Zuranolone: First Approval
Zuranolone (ZURZUVAE™) is an oral neuroactive steroid and a positive allosteric modulator of the gamma aminobutyric ...
Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) remains a disease with poor survival. The pathogenesis is complex and encompasses mult...
Lotilaner Ophthalmic Solution 0.25%: First Approval
Lotilaner Ophthalmic Solution 0.25%: First Approval
Lotilaner ophthalmic solution 0.25% (XDEMVY™), a gamma-aminobutyric acid-gated chloride channel (GABA-Cl) inhibitor ...
Tafolecimab: First Approval
Tafolecimab: First Approval
Tafolecimab (SINTBILO®), a subcutaneously administered anti-proprotein convertase subtilisin/kexin type 9 enzyme&...
Pozelimab: First Approval
Pozelimab: First Approval
Pozelimab (pozelimab-bbfg; VEOPOZ™) is a fully human immunoglobulin (Ig) G4P (i.e. IgG4 with a proline substitution ...
The Place of Cannabinoids in the Treatment of Gynecological Pain
The Place of Cannabinoids in the Treatment of Gynecological Pain
Cannabis sativa (L), a plant with an extensive history of medicinal usage across numerous cultures, has received increased...
Current Medical Therapy for Adenomyosis: From Bench to Bedside
Current Medical Therapy for Adenomyosis: From Bench to Bedside
Adenomyosis, characterized by the growth of endometrial tissue within the uterine wall, poses significant challenges in tr...
Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review
Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review
Hyperuricemia with consequent monosodium urate crystal deposition leads to gout, characterized by painful, incapacitating ...
Talquetamab: First Approval
Talquetamab: First Approval
Talquetamab (talquetamab-tgvs; TALVEY®), a humanized, bispecific G-protein coupled receptor family C group 5 member D...
Correction to: Ritlecitinib: First Approval
Correction to: Ritlecitinib: First Approval
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International ...
Avacincaptad Pegol: First Approval
Avacincaptad Pegol: First Approval
Avacincaptad pegol (IZERVAY™; formerly Zimura®) is a complement C5 inhibitor that is being developed by IVERIC ...
Continued Opioid Use and Adverse Events Following Provision of Opioids for Musculoskeletal Pain in the Emergency Department: A Systematic Review and Meta-Analysis
Continued Opioid Use and Adverse Events Following Provision of Opioids for Musculoskeletal Pain in the Emergency Department: A Systematic Review and Meta-Analysis
The prevalence of continued opioid use or serious adverse events (SAEs) following opioid therapy in the emergency departme...
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments
Alcohol is a prominent cause of liver disease worldwide with higher prevalence in developed nations. The spectrum of alcoh...
Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy
Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and a frequent cause ...
Befotertinib: First Approval
Befotertinib: First Approval
Befotertinib (Surmana®) is an orally administered, highly selective, third-generation epidermal growth factor recepto...
阅读更多
format_indent_increase